Pentobarbitalやmidazolam の持続静注から離脱困難な難治性てんかん発作重積に対する非経静脈的phenobarbital大量療法

  • 須藤 章
    国立精神・神経センター武蔵病院小児神経科 国立精神・北海道大学医学部小児科
  • 須貝 研司
    国立精神・神経センター武蔵病院小児神経科
  • 宮本 健
    国立精神・神経センター武蔵病院小児神経科
  • 三牧 正和
    国立精神・神経センター武蔵病院小児神経科
  • 福水 道郎
    国立精神・神経センター武蔵病院小児神経科
  • 花岡 繁
    国立精神・神経センター武蔵病院小児神経科
  • 佐々木 征行
    国立精神・神経センター武蔵病院小児神経科

書誌事項

タイトル別名
  • Non-Intravenous High-Dose Phenobarbital Therapy for Status Epilepticus Refractory to Continuous Infusion of Midazolam or Pentobarbital: Report of Three Cases.

この論文をさがす

抄録

The management of refractory status epilepticus (RSE) is crucial in preventing neurologic impairment.Although a variety of treatments for RSE including continuous infusion of midazolam (MDL) or pentobarbital (PTB) have been carried out, they are not always effective. Intravenous very-high-dose phenobarbital (PB) has been recommended as having many advantages in the United States, but is not available in Japan.<BR>We treated 3 patients suffering from long term RSE with non-intravenous high-dose PB (NIHDPB). T h e i r seizures were not controlled by continuous infusion of MDL and/or PTB. PB was initially given intramuscularly or rectally and then orally. Within a few or ten days, seizures were completely controlled, and consiousness level g r a dually improved in all cases. The serum levels of PB at seizure control ranged from 50 to 58μg/ml. The epilepti form activities on EEG nearly disappeared in the absence of the burst suppression pattern. Hypotention and respiratory depression did not develop during NIHDPB. Elevated gamma-GTP levels with normal hepatic transaminases were seen in all cases, but it was not necessary to discontinue NIHDPB. NIHDPB may be one of the most effective and safe treatments in Japan for status epileptics refractory to continuous infusion of MDL or PTB.

収録刊行物

  • 脳と発達

    脳と発達 34 (1), 23-29, 2002

    THE JAPANESE SOCIETY OF CHILD NEUROLOGY

被引用文献 (7)*注記

もっと見る

参考文献 (12)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ